Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches
Inflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the ext...
Main Authors: | , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-04-01
|
Series: | Therapeutic Advances in Gastroenterology |
Online Access: | https://doi.org/10.1177/17562848211006669 |
id |
doaj-420826fec6b048e18ce6cc197bf65888 |
---|---|
record_format |
Article |
spelling |
doaj-420826fec6b048e18ce6cc197bf658882021-04-27T22:03:45ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482021-04-011410.1177/17562848211006669Novel trends with biologics in inflammatory bowel disease: sequential and combined approachesGiuseppe PriviteraDaniela PuglieseLoris Riccardo LopetusoFranco ScaldaferriMatteo NeriLuisa GuidiAntonio GasbarriniAlessandro ArmuzziInflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the extent of their efficacy might be, at least partially, dependent on the timing of their introduction and on the subsequent management strategy. In this complex landscape, the potential role for a more dynamic approach with treatments based on sequencing and combining targeted therapies has been explored only minimally so far. In this review, we aim to explore the potential biological rationale behind the use of sequential and combination therapies in IBD, to summarise the current knowledge on this topic and to propose a management algorithm that combines these notions.https://doi.org/10.1177/17562848211006669 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Giuseppe Privitera Daniela Pugliese Loris Riccardo Lopetuso Franco Scaldaferri Matteo Neri Luisa Guidi Antonio Gasbarrini Alessandro Armuzzi |
spellingShingle |
Giuseppe Privitera Daniela Pugliese Loris Riccardo Lopetuso Franco Scaldaferri Matteo Neri Luisa Guidi Antonio Gasbarrini Alessandro Armuzzi Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches Therapeutic Advances in Gastroenterology |
author_facet |
Giuseppe Privitera Daniela Pugliese Loris Riccardo Lopetuso Franco Scaldaferri Matteo Neri Luisa Guidi Antonio Gasbarrini Alessandro Armuzzi |
author_sort |
Giuseppe Privitera |
title |
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches |
title_short |
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches |
title_full |
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches |
title_fullStr |
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches |
title_full_unstemmed |
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches |
title_sort |
novel trends with biologics in inflammatory bowel disease: sequential and combined approaches |
publisher |
SAGE Publishing |
series |
Therapeutic Advances in Gastroenterology |
issn |
1756-2848 |
publishDate |
2021-04-01 |
description |
Inflammatory bowel disease (IBD) management has changed dramatically over the past 20 years, after the introduction of targeted biological therapies. However, the impact of these new drugs in changing the natural history of disease is still under debate. Recent evidence seems to suggest that the extent of their efficacy might be, at least partially, dependent on the timing of their introduction and on the subsequent management strategy. In this complex landscape, the potential role for a more dynamic approach with treatments based on sequencing and combining targeted therapies has been explored only minimally so far. In this review, we aim to explore the potential biological rationale behind the use of sequential and combination therapies in IBD, to summarise the current knowledge on this topic and to propose a management algorithm that combines these notions. |
url |
https://doi.org/10.1177/17562848211006669 |
work_keys_str_mv |
AT giuseppeprivitera noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches AT danielapugliese noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches AT lorisriccardolopetuso noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches AT francoscaldaferri noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches AT matteoneri noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches AT luisaguidi noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches AT antoniogasbarrini noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches AT alessandroarmuzzi noveltrendswithbiologicsininflammatoryboweldiseasesequentialandcombinedapproaches |
_version_ |
1721505546300817408 |